Search

Lenacapavir Regulatory Approval

Global Health Watch: Next steps in LEN for PrEP rollout, new UNAIDS report, reprieve for South Africa and the latest in AVAC’s lawsuit

This week the Global Fund and Gilead announced next steps in the process to rollout injectable lenacapavir, the new UNAIDS Global AIDS Update was released, and South Africa saw a partial reprieve for NIH-funded research. We also track AVAC’s court case against the foreign aid freeze and Congressional advocacy to protect NIH funding.

Now What with Injectable LEN for PrEP?

The announcements on 9 July 2025 from Global Fund and Gilead about their next steps for
injectable lenacapavir (LEN) for PrEP are welcome, as one more part of the process. But they raise
as many questions as they answer. This brief summary is intended to help outline what is actually
known – and not – and what needs to happen nex

PrEP Implementation — What’s worked and what are we learning

IAS 2025 Conference

This year’s IAS Conference comes at a defining moment. Dramatic scientific advances are within reach, but global funding cuts are placing these innovations at risk. All this is jeopardizing the gains that communities, advocates, and researchers have fought for decades to achieve. Click for more, including our roadmap highlighting sessions where prevention and the larger issues of global health equity and sustainability are in the spotlight.

IAS 2025 Resources for Advocates

Re-Imagining Prevention: Ensuring sustainable PrEP access in an evolving funding context

Global Health Watch: Congress Passes “Big Bad Betrayal” Tax Bill, USAID Closes, Key Supreme Court Rulings

This week we saw Congress pass the President’s US domestic policy agenda that will rob approximately 17 million Americans of access to health care in order to provide tax cuts and workarounds for the rich. We also saw the official closure of USAID; restructuring of WHO leadership amid funding shortfalls; the US Supreme Court’s ruling preserving preventive care, including PrEP, and another ruling limiting federal courts’ ability to block presidential actions.

Years Ahead in HIV Prevention Research: Time to Market

This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.

The Trial Design Academy (TDA): For next generation HIV prevention research

AVAC’s Trial Design Academy convenes HIV prevention advocates from across the globe to help shape decisions to move the research agenda forward.